Participated · Series A · Jul 2026

Brenus Pharma is advancing an off-the-shelf platform in immuno-oncology that mimics tumor protein expression to make tumors visible to the immune system. Its lead clinical-stage asset is STC-1010 (NCT06934538), targeting MSS metastatic colorectal cancer, and recent execution across clinical, regulatory and business development milestones has been highlighted by the company. Brenus positions its technology for multi-asset expansion and plans to use new capital to complete the Phase I program for STC-1010 and to advance its next drug candidate. The company has raised a total of €38 million since inception following the €11 million Series A extension. The firm announced the financing from Lyon, France and continues engaging both existing and new international investors to support its development plans.

Participated · Equity · May 2026

Founded in 2020 and based in Nevers, Losanje designs and produces clothing made from recovered materials through upcycling. The company has invested prior proceeds into R&D and the deployment of an industrial tool to support production. With a recent €6.7 million raise on top of a €2.7 million 2023 round, Losanje is targeting consolidation and structuring of its value chain. Management aims to use the new funding to enable large-scale production projects for partner brands. The articles do not provide revenue, user metrics, or details on investors.

Led · Series A · Apr 2026

HEPTA Medical develops a device that integrates a minimally invasive thermal ablation probe introduced via natural orifices to destroy early lung tumors by heat. The company highlights a large unmet need given more than 2.2 million new lung cancer cases and roughly 1.8 million deaths annually worldwide. Founded in 2019 and based in Suresnes, HEPTA employs around a dozen people. Financially, it has just closed a €10 million Series A to fund growth and hiring. The startup plans to initiate its first clinical trials in the second quarter of 2026. Its investor base includes UI Investissement and Supernova Invest as new participants alongside Bpifrance, M & L, Sofinnova Partners, Cléry and MD Start.

Led · Equity · Feb 2026

Founded in September 2023, Greez offers an innovative digital platform dedicated to giving a second life to unsold cosmetic goods. By connecting manufacturers with channels that can legally and profitably repurpose these inventories, the startup helps brands cut their environmental footprint while meeting strict financial and regulatory constraints. The solution targets one of the industry’s most pressing problems—managing excess stock in line with the AGEC anti-waste law. Having quickly become a trusted partner for cosmetic companies, Greez now plans to broaden its reach into pharmacies and major retail chains across France. Longer term, the team intends to roll out the service across Europe. The company has just secured €627 000 to finance this expansion, underscoring investor confidence in its model and growth prospects.

Participated · Seed · Feb 2026

Founded in 2019 in Nantes, France, Eclore Actuators produces protective bellows for industrial robots that are five times more durable than conventional covers, lasting up to a year instead of the typical two months. The durability comes from a proprietary manufacturing process that forms the folds from a single continuous piece, eliminating glued or welded joints that usually constitute weak points. The 11-person startup recently moved into a 700 m² factory on the outskirts of Nantes to scale production. Eclore targets two complementary industrial markets: retrofitting robots already in service for quick, near-term sales, and supplying SCARA and other robot manufacturers for long-term, recurring revenue; it has already secured a series-production contract with Swiss manufacturer Stäubli and is negotiating with multiple Japanese robotics giants. Beyond industry, the company is prototyping its membrane technology as a directional “airbag” to eject drones or payloads for defense applications, with commercialization expected in about two years. Management expects industrial sales to account for more than 80 % of revenue over the next five years, while the fresh capital will fund increased production capacity and international commercial expansion, particularly in Japan.